Vermillion Shares Reduced, Inhibitex Stock a Buy, Corcept Has Promising Drug, Sun Healthcare Price Target Rises

At closing on Thursday, the Dow Jones Industrial Average (NYSEARCA:DIA) closed at 12,415. The S&P 500 (NYSEARCA:SPY) closed at 1,281, and the Nasdaq (NASDAQ:QQQ) closed at 2,669. Here’s what top fleet analyst firms had to say about the following companies and their respective businesses:

Vermillion, Inc. (NASDAQ:VRML): Roth Capital lowered target on Vermillion from $4 to $3.50. Roth Capital feels slow reorder rates are impeding revenue growth and there is still some uncertainty about reimbursement. The firm feels positive about the announced restructuring and maintains a Buy rating.

Inhibitex Inc. (NASDAQ:INHX): Wedbush says buy Inhibitex on recent weakness. The firm cites expansion of the interferon-free INX-189 trial and a new study of an INX-189 combination providing company momentum. Wedbush reiterating its Outperform rating.

Hersha Hospitality Trust (NYSE:HT): RW Baird names Hersha Hospitality top hotel REIT pick for 2012. Baird feels Hersha Hospitality has created a unique to leverage consumer bias towards urban and select-service hotels. With half of Hersha Hospitality’s EBITDA margins, the highest among peers, in the New York City hotel, Baird doesn’t believe current price includes potential. The firm rate HT Outperform  with a target of $6.

Corcept Therapeutics Inc. (NASDAQ:CORT): Corcept Therapeutics’ Korlyn may be nearing approval. A treatment fpr ushing’s syndrome, Korlyn has a February 17 Prescription Drug User Fee Act date. After examining PDUFA data, Leerink says since no risk evaluation and management strategy (REMS), and no panel will be required, approval should be granted. While Leerink says its warming up to Corcept Therapeutics, reiterating a Market Perform, BioLogic Equity initiated Corcept Therapeutics coverage with a Sell rating.

Sun Healthcare Group, Inc. (NASDAQ:SUNH): Credit Suisse raised its target for Sun Healthcare from $3 to $5 and expects the company to move higher than 2012 guidance. The firm said cost reduction efforts are working at the company, but they still have concerns about Medicare payment rates. The firm rates SUNH Neutral.

To contact the reporter on this story: Jim Wilkerson at staff.writers@wallstcheatsheet.com

To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com